+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the inhalation suspension of ensifentrine, given twice daily via a standard jet nebulizer, for its effects on people with non-cystic fibrosis bronchiectasis NCFBE. This randomized, double-blind, placebo-controlled Phase II study aims to assess the safety and efficacy of ensifentrine compared to placebo over up to 52 weeks. The main focus is to see how ensifentrine affects lung flare-ups, symptoms, and quality of life in participants who continue their standard care. Participants will be randomly assigned to receive either 3 mg of nebulized ensifentrine or a matching placebo, both administered twice daily through a jet nebulizer for up to 52 weeks. Neither participants nor study staff will know which treatment is given. Some participants may finish earlier if the study ends after the last participant completes the 24-week visit. This trial compares the study drug to placebo while all participants receive their usual care. During the study, participants will be monitored regularly with lung function tests, symptom questionnaires, and quality of life assessments at baseline and at several points up to 24 weeks and through study completion. Researchers will measure the rate of lung exacerbations and track adverse events for up to 52 weeks. Additional pharmacokinetic tests will be done in a sub-study. Participants will be expected to perform spirometry and provide sputum samples, and their medication adherence and safety will be closely followed throughout the study period.

Age: 18Years - 80YearsAll GendersPhase 2
51 locations
P

Actively Recruiting

Researchers are evaluating the use of Mobilization and Tactile Stimulation MTS, a hands-on physical therapy technique, to help adults who have had a stroke and are experiencing unilateral neglect, a condition where they are unaware of one side of their body. This study focuses on stroke survivors aged 18 and over who are more than 20 weeks post-stroke and have signs of neglect. The study aims to better understand how MTS affects neglect using detailed measurements because its effectiveness has not been widely studied. The study includes three phases over approximately ten weeks. First, there is a two-week baseline phase without MTS treatment, followed by a six-week treatment phase where participants receive MTS therapy for 45 to 60 minutes, five days a week. The final two-week phase involves withdrawal of treatment with continued assessments. MTS therapy involves joint movements, massage, touch, compression, and selective joint movement of the affected arm and hand, delivered at home or a convenient hospital setting. Participants will be assessed twice weekly by a research therapist using three tests for neglect the Letter Cancellation Test, the Catherine Bergego Scale, and the Fluff Test. Carers will be trained to perform daily assessments using the Catherine Bergego Scale. After completing the study, participants and carers may take part in interviews to share their experiences. The study includes safety monitoring for risks like arm discomfort, which can be managed by adjusting therapy. Overall, involvement lasts about three months with regular therapy and evaluations.

Age: 18Years +All GendersPhase Not Applicable
1 location